Evidence map›Paper›PMID 36440638›Full record

ArticleEpidemiology and infection2022

Epidemiological evaluation of mass testing in a small municipality in the Netherlands during the SARS-CoV-2 epidemic.

Lisanne Heijmink, Juul Tönis, Niek Gilhuis, Maartje Gerkema, Lotte Hart, Stijn Raven, Jossy van den Boogaard, Agnetha Hofhuis, Susan van den Hof, Olga Visser

Abstract read
In one paragraph

Article in Epidemiology and infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lisanne HeijminkMunicipal Health Service Utrecht region, Zeist, the Netherlands.ORCID 0000-0003-2477-8661
Juul TönisMunicipal Health Service Utrecht region, Zeist, the Netherlands.
Niek GilhuisMunicipal Health Service Utrecht region, Zeist, the Netherlands.
Maartje GerkemaMunicipal Health Service Utrecht region, Zeist, the Netherlands.
Lotte HartSeeder de Boer, Amsterdam, the Netherlands.
Stijn RavenMunicipal Health Service Utrecht region, Zeist, the Netherlands.
Jossy van den BoogaardCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Agnetha HofhuisCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Susan van den HofCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Olga VisserMunicipal Health Service Utrecht region, Zeist, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During 6 weeks in February-March 2021, the Dutch municipal health service Utrecht studied the epidemiological effects on test incidence and the detection of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with mass testing (MT). During MT, inhabitants of Bunschoten could repeatedly test regardless of symptoms and as often as desired at the close-by test facilities in the municipality. Data from the regular COVID-19 registration was used for analysis. In Bunschoten, MT caused a significant increase in test incidence and an immediate increase in the number of detected active infections, in contrast to a stabilisation in the rest of the province of Utrecht. Age distribution of test incidence shifted to the older population in Bunschoten during MT. During MT, there was a 6.8 percentage point increase in detected asymptomatic cases, a 0.4 percentage point increase in pre-symptomatic cases and a decrease of 0.5 days between onset of symptoms and test date. This study has shown that MT increases test incidence and helps to obtain a more complete view of the presence of SARS-CoV-2 in a community, which can be useful in specific situations with a defined target group or goal. However, the question remains open whether the use of MT is proportionate to the overall gain.

Indexed as

COVID-19SARS-CoV-2HumansNetherlandsCOVID-19COVID-19 testingmass screeningNetherlandsSARS-CoV-2

Identifiers

PMID36440638
PMCPMC9744447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.